FLT3 and acute myeloid leukemia: The activity of the oral FLT3i Pexidartinib, with interesting in vitro efficacy against the conferring resistance mutation F691L, was explored in a phase I trial with a dose escalation phase at daily doses ranging from 800 to 5000 mg in 34 patients, without dose limiting toxicities, followed by a dose expansion phase of 3000 mg daily dose in 56 R/R FLT3 AML patients [100].